Overview


According to FutureWise analysis the market for drug screening in 2023 is US$ 7.3 billion, and is expected to reach US$ 24.43 billion by 2031 at a CAGR of 16.30%.

Drug screening involves examining individuals for drug usage even if they don't necessarily exhibit any signs of drunkenness or a substance use disorder. It could be carried out methodically or at random in certain demographics, including those of students, athletes, and convicts. In the process of drug screening a sample of urine, blood, breath, saliva, sweat, or hair may be tested. Urine testing is the most commonly used method because it is non-invasive, quick, and capable of detecting a wide range of drugs. It can detect drugs used within 1 to 4 days, or even longer depending on the drug. Blood testing is rarely used because it is invasive and can only detect drugs a few hours after they have been used. Hair testing is less common, but it can detect some drugs if they were used within the previous 100 days.

Government agencies' strict regulations requiring alcohol and drug screening for safety reasons as well as rising efforts to track and combat substance usage are expected to boost the market growth. Also, the prevalence of substance misuse is rising globally, which has increased the necessity for screening and fuelled the demand for drug screening. Furthermore, the COVID-19 pandemic's consequences on job losses, business closures, and the economy have had a detrimental impact on people's mental health and raised rates of substance abuse. According to CDC, 13.3% of Americans started or increased substance addiction to deal with COVID-19-related anxiety or feelings, which led to a significant increase in the need for drug screening.

FutureWise Market Research has published a report that provides an insightful analysis of drug screening market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the drug screening market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Abbott
  • Dragerwerk
  • Labcorp
  • Quest Diagnostics
  • Alfa Scientific Designs
  • Lifeloc
  • MPD Inc.
  • Orasure
  • Omega Laboratories
  • Premier Biotech
  • Psychemedics
  • Roche
  • Shimadzu
  • Siemens Healthineers 
  • Thermo Fisher Scientific

(Note: The list of the major players will be updated with the latest market scenario and trends)

The COVID-19 outbreak led to an increase in drug and alcohol abuse, as mental health issues were on the rise. Similarly, narcotics traffickers have recovered from the initial difficulties caused by the pandemic lockdown thanks to technological advances and virtual currency transactions that operate outside of the traditional banking system, providing greater anonymity. These factors are expected to increase the demand for products and services related to drug testing. Increased awareness of the dangers of driving while intoxicated, as well as alcohol and drug restrictions in businesses and government organizations, are expected to limit the growth of the global drug screening market. However, alcohol restrictions in many Islamic countries, as well as a lack of infrastructure in developing economies, are expected to limit global consumption. With rising drug resistance and the emergence of new diseases, the need for new drug development is at an all-time high. This fact has prompted significant recent efforts to develop new drugs as well as novel techniques for efficient drug screening. However, new drug development is frequently hampered by cost and time constraints.

As a result, more accessible and cost-effective drug screening methods are required. A microfluidic-based system outperforms traditional drug screening methods in terms of sample consumption, reaction time, and operation cost. Recently developed microfluidic chip technology has proven to be an excellent choice for drug screening at the cellular level. Microfluidic devices are made up of microstructures that closely resemble the extracellular environment and allow for flexible drug concentration adjustment. Furthermore, because microfluidics easily generates laminar flow, they aid in monitoring the dose-response of a drug by minimizing cell damage caused by fluid turbulence. Microfluidic devices are automated and multiplexed, allowing cells to be cultured on the same chip at the same time, allowing biochemical tests to be performed without the use of numerous reagents. The target market is anticipated to increase rapidly as a result of these developments in the field of drug screening.

By Product Type

  • Analytical Instruments
    •     Immunoassay Analyzers
    •    Chromatography Instruments
    •    Breathalyzers
      •        Fuel Cell Breathalyzers
      •         Semiconductor Breathalyzers
      •         Other Breathalyzers
  • Rapid Testing Devices
    •    Urine Testing Devices
      •        Drug Testing Cups
      •        DIP Cards
      •        Drug Testing Cassettes
    •     Oral Fluid Testing Devices
  • Consumables
    •    Assay Kits
    •    Sample Collection Devices
    •    Calibrators and Controls
    •    Other Consumables

By Drug Screening Services

  • Regulated
  • Non-Regulated

By Sample Type

  • Urine Samples
  • Breath Samples
  • Oral Fluid Samples
  • Hair Samples
  • Other Samples

By End-user

  • Workplace
  • Criminal Justice Systems and Law Enforcement Agencies
  • Drug Treatment Centers
  • Pain Management Centers
  • Schools and Colleges
  • Hospitals
  • Individual Users
  • Drug Testing Laboratories

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Some of the main drivers of the region's leading share include the existence of significant firms executing substantial expansion strategies and strict laws for workplace testing. Also, the region's high adoption of technologically advanced solutions and advantageous reimbursement circumstances have contributed to the market's expansion. Globally, analytical tools registered a 43.6% market share based on product segment. Lab-based testing will dominate the market in 2022 by testing type registering 63.1% share. Also, in 2022, the global market for urine samples registered 49.6% share.

  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the Drug Screening Market By Product Type, By Drug Screening Services, By Sample Type, By End-user, and By Region. 
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Drug Screening Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Drug Screening Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Drug Screening Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Drug Screening Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Analytical Instruments
         1.1. Immunoassay Analyzers
         1.2. Chromatography Instruments
         1.3. Breathalyzers
          1.3.1. Fuel Cell Breathalyzers
          1.3.2. Semiconductor Breathalyzers
          1.3.3. Other Breathalyzers
        2. Rapid Testing Devices
         2.1. Urine Testing Devices
          2.1.1. Drug Testing Cups
          2.1.2. DIP Cards
          2.1.3. Drug Testing Cassettes
         2.2. Oral Fluid Testing Devices
        3. Consumables
         3.1. Assay Kits
         3.2. Sample Collection Devices
         3.3. Calibrators and Controls
         3.4. Other Consumables

  • 8.   Drug Screening Market, By Drug Screening Services Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Regulated
        2. Non-Regulated

  • 9.   Drug Screening Market, By Sample Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Urine Samples
        2. Breath Samples
        3. Oral Fluid Samples
        4. Hair Samples
        5. Other Samples

  • 10.   Drug Screening Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Workplace
        2. Criminal Justice Systems and Law Enforcement Agencies
        3. Drug Treatment Centers
        4. Pain Management Centers
        5. Schools and Colleges
        6. Hospitals
        7. Individual Users
        8. Drug Testing Laboratories

  • 11.   North America Drug Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Drug Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Drug Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Drug Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Dragerwerk
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Labcorp
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Quest Diagnostics
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Alfa Scientific Designs
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lifeloc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. MPD Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Orasure
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Omega Laboratories
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Premier Biotech
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Psychemedics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Roche
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Shimadzu
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Siemens Healthineers
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Thermo Fisher Scientific
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients